Skip to main content
NXTC
NASDAQ Life Sciences

10% Owner ADAR1 Capital Management Pours $1.6M into NextCure at $4.80–$5.00

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.168
Mkt Cap
$17.903M
52W Low
$1.55
52W High
$15.74
52W Position info
169% above low
Off High info
74% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

NXTC has more than doubled off its 52-week low of $1.55 on light trading volume (0.2× avg).

Summary

10% owner ADAR1 Capital Management bought $1.6M of NextCure stock at $4.80–$5.00, increasing its stake to 722,419 shares. The purchase comes amid a pending merger that will heavily dilute existing holders.


Key Events · Ownership and Investor Activity · NXTC

  • $1.6M Purchase by 10% Owner

    ADAR1 Capital Management and Daniel Schneeberger acquired 329,153 shares for $1,624,120.50 at prices ranging from $4.80 to $5.00 on July 30–31, 2026.

  • Stake Increased to 722,419 Shares

    Post-transaction holdings total 722,419 shares, representing a significant increase from the prior 393,266 shares reported on July 29.

  • Merger Context

    The purchase follows the July 14 announcement of a merger with Avere Therapeutics that will leave legacy NextCure stockholders with only ~1.89% of the combined company.

  • Financial Investor Signal

    As a 10% owner, ADAR1's purchase reflects portfolio conviction rather than operational insider knowledge, but the size and timing near the merger vote suggest a bet on value realization.


Analysis · NXTC · Life Sciences

A $1.6 million purchase of NextCure stock by 10% owner ADAR1 Capital Management over two days, at prices near the current $4.17 level, signals a significant commitment from a large institutional holder. The move comes just weeks after the company announced a merger that would leave legacy shareholders with only ~1.89% of the combined entity, suggesting the fund sees value in the current price—potentially as a bet on the merger closing or on the underlying pipeline. Because the buyer is a 10% owner rather than a company executive, the signal is financial rather than operational: it reflects portfolio conviction, not insider knowledge of business developments.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NXTC was trading at $4.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.9M. The 52-week trading range was $1.55 to $15.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NXTC - Latest Insights

NXTC
Nov 10, 2026, 4:25 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.78
Real-time Price: $6.68 info
Change: +$0.900 (+16%) info
Market Cap: $30.588M info
NXTC
Nov 10, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.78
Real-time Price: $6.68 info
Change: +$0.900 (+16%) info
Market Cap: $30.588M info
NXTC
Nov 10, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.78
Real-time Price: $6.68 info
Change: +$0.900 (+16%) info
Market Cap: $30.588M info
NXTC
Oct 30, 2026, 8:39 PM EDT
Filing Type: S-4/A
Importance Score:
8
Price at Filing: $6.31
Real-time Price: $6.68 info
Change: +$0.370 (+6%) info
Market Cap: $30.588M info
NXTC
Sep 30, 2026, 7:36 PM EDT
Filing Type: S-4/A
Importance Score:
9
Price at Filing: $5.01
Real-time Price: $6.68 info
Change: +$1.67 (+33%) info
Market Cap: $30.588M info